Clinical trial
SWitching to Abilify Trial (SWAT)
NCT00304616 · Korea Otsuka Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00304616 |
|---|---|
| Title | SWitching to Abilify Trial (SWAT) |
| Official title | A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients |
| Lead sponsor | Korea Otsuka Pharmaceutical Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone |
| Enrollment | 500 |
| Start date | Oct 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Mar 20, 2006 |
| Last update posted | Dec 17, 2009 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: